BCL2 and AL amyloidosis: However, pronounced heterogeneity in the extent of BCL-2 dependence in t(11;14) AL amyloidosis and the clear BCL-2 dependence in some specimens lacking t(11;14) suggest that additional biomarkers may be particularly useful for assigning therapy with BH3 mimetics and especially ABT-199.